32
Participants
Start Date
March 2, 2016
Primary Completion Date
March 8, 2019
Study Completion Date
March 8, 2019
BEBT-908 for injection
"Dose escalation phase:10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase:15 or 22.5mg/m2,intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week,21 days as cycle."
Hunan Cancer Hospital, Changsha
Lead Sponsor
BeBetter Med Inc
INDUSTRY